



## Atea Pharmaceuticals Announces Closing of Initial Public Offering

November 3, 2020

### Full Exercise of the Underwriters' Overallotment Brings Additional \$45 Million

BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the closing of its initial public offering of 14,375,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,875,000 additional shares of common stock, at a public offering price of \$24.00 per share. The aggregate gross proceeds to Atea from the offering were \$345 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Atea Pharmaceuticals. Atea's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "AVIR" on October 30, 2020.

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group L.L.C. and William Blair & Company, L.L.C. acted as joint book-running managers of the offering.

A registration statement on Form S-1 (File No. 333-249404) relating to the offering has been filed with the Securities and Exchange Commission and became effective on October 29, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at [prospectus@morganstanley.com](mailto:prospectus@morganstanley.com); Evercore Group, L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [ecm.prospectus@evercore.com](mailto:ecm.prospectus@evercore.com); or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at [prospectus@williamblair.com](mailto:prospectus@williamblair.com).

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### Contacts

Investors:

Will O'Connor

Stern Investor Relations

212-362-1200

[will.oconnor@sternir.com](mailto:will.oconnor@sternir.com)

Media:

Carol Guaccero

301-606-4722

[contactus@ateapharma.com](mailto:contactus@ateapharma.com)